A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: Centralized pathology review and overall survival compared with the general population

Charlotte Gerd Hannibal, Russell S Vang, Jette Junge, Kirsten Frederiksen, Anette Kjaerbye-Thygesen, Klaus Kaae Andersen, Ann Tabor, Robert J Kurman, Susanne K. Kjaer

Research output: Contribution to journalArticle

Abstract

Objective To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population. Methods The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. Results A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p = 0.3), whereas women with advanced stage disease had a poorer one (p <0.0001). This was evident both in women with noninvasive (p <0.0001) and invasive implants (p <0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p <0.0001) and noninvasive LGSC (p <0.0001) was poorer than expected from the general population. Conclusions To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalGynecologic Oncology
Volume134
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Denmark
Pathology
Survival
Population
Neoplasms
Carcinoma
Hospital Departments
Medical Records
Registries
Databases

Keywords

  • Centralized pathology review
  • Long-term follow-up
  • Population-based
  • Relative survival
  • Serous "borderline" ovarian tumors

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002 : Centralized pathology review and overall survival compared with the general population. / Hannibal, Charlotte Gerd; Vang, Russell S; Junge, Jette; Frederiksen, Kirsten; Kjaerbye-Thygesen, Anette; Andersen, Klaus Kaae; Tabor, Ann; Kurman, Robert J; Kjaer, Susanne K.

In: Gynecologic Oncology, Vol. 134, No. 2, 2014, p. 267-273.

Research output: Contribution to journalArticle

Hannibal, Charlotte Gerd ; Vang, Russell S ; Junge, Jette ; Frederiksen, Kirsten ; Kjaerbye-Thygesen, Anette ; Andersen, Klaus Kaae ; Tabor, Ann ; Kurman, Robert J ; Kjaer, Susanne K. / A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002 : Centralized pathology review and overall survival compared with the general population. In: Gynecologic Oncology. 2014 ; Vol. 134, No. 2. pp. 267-273.
@article{fb9fa66882e94e9b96e2d27a1eacbbb8,
title = "A nationwide study of serous {"}borderline{"} ovarian tumors in Denmark 1978-2002: Centralized pathology review and overall survival compared with the general population",
abstract = "Objective To describe the study population and estimate overall survival of women with a serous {"}borderline{"} ovarian tumor (SBT) in Denmark over 25 years relative to the general population. Methods The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. Results A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p = 0.3), whereas women with advanced stage disease had a poorer one (p <0.0001). This was evident both in women with noninvasive (p <0.0001) and invasive implants (p <0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p <0.0001) and noninvasive LGSC (p <0.0001) was poorer than expected from the general population. Conclusions To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.",
keywords = "Centralized pathology review, Long-term follow-up, Population-based, Relative survival, Serous {"}borderline{"} ovarian tumors",
author = "Hannibal, {Charlotte Gerd} and Vang, {Russell S} and Jette Junge and Kirsten Frederiksen and Anette Kjaerbye-Thygesen and Andersen, {Klaus Kaae} and Ann Tabor and Kurman, {Robert J} and Kjaer, {Susanne K.}",
year = "2014",
doi = "10.1016/j.ygyno.2014.06.002",
language = "English (US)",
volume = "134",
pages = "267--273",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002

T2 - Centralized pathology review and overall survival compared with the general population

AU - Hannibal, Charlotte Gerd

AU - Vang, Russell S

AU - Junge, Jette

AU - Frederiksen, Kirsten

AU - Kjaerbye-Thygesen, Anette

AU - Andersen, Klaus Kaae

AU - Tabor, Ann

AU - Kurman, Robert J

AU - Kjaer, Susanne K.

PY - 2014

Y1 - 2014

N2 - Objective To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population. Methods The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. Results A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p = 0.3), whereas women with advanced stage disease had a poorer one (p <0.0001). This was evident both in women with noninvasive (p <0.0001) and invasive implants (p <0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p <0.0001) and noninvasive LGSC (p <0.0001) was poorer than expected from the general population. Conclusions To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.

AB - Objective To describe the study population and estimate overall survival of women with a serous "borderline" ovarian tumor (SBT) in Denmark over 25 years relative to the general population. Methods The Danish Pathology Data Bank and the Danish Cancer Registry were used to identify 1487 women diagnosed with SBTs from 1978 to 2002. The histologic slides were collected from Danish pathology departments and reviewed by expert pathologists and classified as SBT/atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Associated implants were classified as noninvasive or invasive. Medical records were collected from hospital departments and reviewed. Data were analyzed using Kaplan-Meier and relative survival was estimated with follow-up through September 2, 2013. Results A cohort of 1042 women with a confirmed SBT diagnosis was identified. Women with stage I had an overall survival similar to the overall survival expected from the general population (p = 0.3), whereas women with advanced stage disease had a poorer one (p <0.0001). This was evident both in women with noninvasive (p <0.0001) and invasive implants (p <0.0001). Only among women with advanced stage, overall survival of women with SBT/APST (p <0.0001) and noninvasive LGSC (p <0.0001) was poorer than expected from the general population. Conclusions To date this is the largest nationwide cohort of SBTs where all tumors have been verified by expert pathologists. Only in women with advanced stage SBT, overall survival is poorer than in the general population which applies both to women with noninvasive and invasive implants as well as to women with SBT/APST and noninvasive LGSC.

KW - Centralized pathology review

KW - Long-term follow-up

KW - Population-based

KW - Relative survival

KW - Serous "borderline" ovarian tumors

UR - http://www.scopus.com/inward/record.url?scp=84905572147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905572147&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2014.06.002

DO - 10.1016/j.ygyno.2014.06.002

M3 - Article

C2 - 24924123

AN - SCOPUS:84905572147

VL - 134

SP - 267

EP - 273

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -